BackSofgen Pharma S.A. Overview
Sofgen Pharma S.A.

Sofgen Pharma S.A. Return on Equity

Sofgen Pharma S.A. (PROCF) has a ROE of 19211.43%, above the Healthcare sector average of 13.1%.

Get informed when a big investor buys or sells

+ Follow

ROE

19211.43%

Return on Equity

19211.43%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Sofgen Pharma S.A. (PROCF) FAQ

As of the most recent data, PROCF shows a ROE of 19211.43%. That is above the Healthcare sector average of 13.1%. Scroll down for historical charts and peer comparison views.

The Healthcare sector average ROE is about 13.1%. Sofgen Pharma S.A. is at 19211.43%, which is higher that average. That is roughly 146509.6% above the sector mean. Use the comparison chart on this page to see how PROCF stacks up against individual peers as well.

Check the historical chart to see whether PROCF's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Sofgen Pharma S.A. with peers to see if the move is company-specific or sector-wide.

Besides this return on equity page, Stockcircle has Sofgen Pharma S.A.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 19211.43%) with ownership activity and broader fundamentals.

The Healthcare average ROE is about 13.1%, while PROCF is at 19211.43%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.